Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2007-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To establish the efficacy and Safety of rHu-EPO-alpha in patients with anemia of Chronic Renal Failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins

NCT00211029

Red-Cell Aplasia, Pure

COMPLETED

Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis

NCT02586402

Chronic Renal Failure Anemia Dialysis

UNKNOWN PHASE2

Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease

NCT04959578

Anemia of Chronic Kidney Disease

COMPLETED PHASE4

Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia

NCT00954486

Anemia

WITHDRAWN NA

Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients

NCT05699109

Anemia of Chronic Kidney Disease Chronic Renal Failure Chronic Renal Failure Anemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite impressive advances in the safety of the blood supply, the search for therapeutic alternatives to blood continues. Recombinant Human Erythropoietin (rHu-EPO), along with iron, vitamin B12, and folic acid, has been recommended as a specific medication that should be used instead of blood transfusion if the clinical condition of the patient permits sufficient time for these agents to promote erythropoiesis.

In normal physiological conditions Erythropoietin is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. rHu-EPO is a glycoprotein which stimulates red blood cell production. Epoetin alfa, a 165 amino acid glycoprotein manufactured by recombinant DNA technology, has the same biological effects as endogenous rHu-EPO.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recombinant Human Erythropoietin alpha

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients between 18 to 70 yrs of age of either sex.
* CRF patients who are EPO naïve or have been off EPO or similar Erythropoietic drugs for more than 4 weeks, falling with-in CKD stage III to V.
* Patients who are willing to give the consent
* Patient with Anemia of Chronic Renal Failure with Hb \< 10.

Exclusion Criteria

* Patients who are known hypersensitive to rHu-EPO.
* Patient's with history of anemia due to causes other than anemia of CRF.
* Patient's with history of Active infections, Hemoglobinopathies, Neoplastic diseases, and HIV infection.
* Patient's with history of G.I. bleeding (Overt or Occult).
* Patient's with history of serious or unstable medical or psychological conditions that could compromise the patient's safety or successful trial participation.
* Patients with abnormal liver function test. However, patients with HBsAg and HCV positive shall be included provided their Transaminases are normal.
* Female patient's of child bearing potential and not having undergone permanent sterilization procedures. Pregnant and lactating female patients.
* Patients unwilling or unable to comply with the study procedures. Chronic alcoholic or drug abuse patients

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No